Spontaneous Coronary Artery Dissection in a 26-Year-Old-Male Soldier.
Authors: Guess JM, Madigan CG, Hudspath CB, Hurley JT, Martinho S
Abstract
Spontaneous coronary artery dissection (SCAD) is an uncommon cause of acute coronary syndromes, which has been gaining increased recognition with the routine use of coronary angiography and intravascular imaging techniques in patients presenting with ST-elevation myocardial infarction. Here we report the case of a healthy, 26-year-old active-duty male presented to Tripler Army Medical Center for evaluation of acute onset and worsening chest pain that occurred shortly after participating in an Army physical fitness test. His initial ...
Source: Military Medicine - September 16, 2018 Category: International Medicine & Public Health Tags: Mil Med Source Type: research
Use of Antiplatelet Agents in the Neurosurgical Patient
This article presents the relevant data supporting the use of antiplatelet agents in vascular neurosurgery and recommendations based on the described studies. (Source: Neurosurgery Clinics of North America)
Source: Neurosurgery Clinics of North America - September 15, 2018 Category: Neurosurgery Authors: Amanda S. Zakeri, Shahid M. Nimjee Source Type: research
Correction of coagulopathy in thrombocytopenia and Glanzmann thrombasthenia models by fibrinogen and factor XIII as assessed by thromboelastometry
In conclusion, the created models may be useful in the development of new ways to correct the impaired coagulation potential in TCP and GT. (Source: Pathophysiology)
Source: Pathophysiology - July 10, 2018 Category: Pathology Source Type: research
Toxins Are an Excellent Source of Therapeutic Agents against Cardiovascular Diseases
Semin Thromb Hemost DOI: 10.1055/s-0038-1661384Venomous and hematophagous animals use their venom or saliva for survival, to obtain food, and for self-defense. Venom and saliva from these animals are cocktails of bioactive molecules primarily composed of proteins and peptides. These molecules are called toxins because they cause unwanted consequences on prey. They exhibit unique, diverse, and specific biological activities that perturb normal physiological processes of their prey and host. However, the potential of toxins as inspirations for the development of therapeutic agents or pharmacological tools has also long been ...
Source: Seminars in Thrombosis and Hemostasis - June 28, 2018 Category: Hematology Authors: Koh, Cho Yeow Modahl, Cassandra M. Kulkarni, Namrata Kini, R. Manjunatha Tags: Review Article Source Type: research
Potential applications of venom peptides as anti-thrombotic agents in arterial & deep-vein thrombosis.
CONCLUSION: Ancrod isolated from Malayan pit viper venom can cause reduction in level of blood fibrinogen and has been effectively tried in various ischemic conditions, including stroke. In order to search for novel lead molecules, the emphasis should be on isolation and characterization of pharmacologically active snake venoms proteins affecting blood coagulation and platelet aggregation. In this review an attempt has been made to recapitulates and discuss venoms of different animals and arthropod having anticoagulant peptides for their potential use in therapeutics and diagnostics.
PMID: 29921198 [PubMed - as sup...
Source: Protein and Peptide Letters - June 13, 2018 Category: Biochemistry Authors: Khan S, Gul A, Noreen R, Ashraf M, Ahmad S, Awan SB Tags: Protein Pept Lett Source Type: research
Activated Clotting Time to Guide Heparin Dosing in Non-ST-Segment-Elevation Acute Coronary Syndrome Patients Undergoing Percutaneous Coronary Intervention and Treated With IIb/IIIa Inhibitors: Impact on Ischemic and Bleeding Outcomes: Insights From the TAO Trial [Coronary Interventions]
Conclusions—
In the TAO trial, peak procedural ACT ≥250 s was associated with increased bleeding risk in non–ST-segment–elevation acute coronary syndrome patients treated with unfractionated heparin plus GPIs. This threshold was increased to 290 s when performing radial approach.
Clinical Trial Registration—
URL: https://www.clinicaltrials.gov. Unique identifier: NCT01076764. (Source: Circulation: Cardiovascular Interventions)
Source: Circulation: Cardiovascular Interventions - June 12, 2018 Category: Cardiology Authors: Dillinger, J.-G., Ducrocq, G., Elbez, Y., Cohen, M., Bode, C., Pollack, C., Nicolau, J. C., Henry, P., Kedev, S., Wiviott, S. D., Sabatine, M. S., Mehta, S. R., Steg, P. G. Tags: Percutaneous Coronary Intervention, Stent, Treatment, Complications, Thrombosis Coronary Interventions Source Type: research
Prolonged use of eptifibatide as a bridge to maintain drug-eluting stent patency in a patient receiving extracorporeal membrane oxygenation.
CONCLUSION: While eptifibatide was effective in maintaining stent patency, our patient experienced several bleeding episodes during ECMO. Thus, the risks and benefits of concurrent antiplatelet and anticoagulant therapy must be appropriately weighed in this patient population. Additionally, as the need for dual antiplatelet therapy due to coronary stent implantation is increasing, further studies are needed to validate optimal dosing of eptifibatide in patients at a high risk of bleeding during ECMO.
PMID: 29874954 [PubMed - as supplied by publisher] (Source: Perfusion)
Source: Perfusion - June 1, 2018 Category: Cardiovascular & Thoracic Surgery Authors: Gurnani PK, Bohlmann A, March RJ Tags: Perfusion Source Type: research
Contemporary Parenteral Antiplatelet Bridging Strategies: A Single-Center Real-World Experience at a Tertiary Care Center.
CONCLUSIONS: Parenteral antiplatelet bridging was used for ~3 days in this single-center, tertiary care experience, commonly for unplanned surgery following PCI. Despite high-risk presentations with >15% in-hospital mortality, efficacy profiles were reassuring with no identified stent thrombosis, but bleeding and dosing errors were common. Antiplatelet bridging should only be used in well-selected patients at the appropriate dose for the minimal necessary duration.
PMID: 29537373 [PubMed - as supplied by publisher] (Source: EuroIntervention)
Source: EuroIntervention - March 17, 2018 Category: Cardiovascular & Thoracic Surgery Tags: EuroIntervention Source Type: research
The Chaperone Protein HSP47: A Platelet Collagen Binding Protein that Contributes to Thrombosis and Haemostasis.
CONCLUSIONS: Our study demonstrates the presence of HSP47 on the platelet surface where it interacts with collagen, stabilises platelet adhesion and increases collagen mediated signalling and therefore thrombus formation and haemostasis. This article is protected by copyright. All rights reserved.
PMID: 29512284 [PubMed - as supplied by publisher] (Source: Thrombosis and Haemostasis)
Source: Thrombosis and Haemostasis - March 7, 2018 Category: Hematology Authors: Sasikumar P, AlOuda KS, Kaiser WJ, Holbrook LM, Kriek N, Unsworth JA, Bye AP, Sage T, Ushioda R, Nagata K, Farndale RW, Gibbins JM Tags: J Thromb Haemost Source Type: research
The Chaperone Protein HSP47: A Platelet Collagen Binding Protein that Contributes to Thrombosis and Haemostasis
ConclusionsOur study demonstrates the presence of HSP47 on the platelet surface where it interacts with collagen, stabilises platelet adhesion and increases collagen mediated signalling and therefore thrombus formation and haemostasis.This article is protected by copyright. All rights reserved. (Source: Journal of Thrombosis and Haemostasis)
Source: Journal of Thrombosis and Haemostasis - March 1, 2018 Category: Hematology Authors: P Sasikumar, K.S AlOuda, W J Kaiser, L.M Holbrook, N Kriek, J.A Unsworth, A.P Bye, T Sage, R Ushioda, K Nagata, R.W Farndale, J M Gibbins Tags: Original Article ‐ Platelets Source Type: research
What is the role for Glycoprotein IIb/IIIa inhibitor use in the catheterisation laboratory in the current era?
CONCLUSION: Because of the persistent benefit of GPI in limiting early ischemic complications, especially in higher risk clinical and/or anatomical subsets, and the associated risk of increased bleeding complications, also in contemporary PCI, these agents should currently be used on a selective rather than routine basis, including bail out administration for peri-procedural thrombotic complications.
PMID: 29345590 [PubMed - as supplied by publisher] (Source: Current Vascular Pharmacology)
Source: Current Vascular Pharmacology - January 16, 2018 Category: Drugs & Pharmacology Authors: Rubboli A, Patti G Tags: Curr Vasc Pharmacol Source Type: research
Platelet collagen receptor Glycoprotein VI ‐dimer recognizes fibrinogen and fibrin through their D‐domains, contributing to platelet adhesion and activation during thrombus formation
ConclusionOnly dimeric GPVI interacts with fibrinogen D‐domain, at a site proximate to its collagen binding site, to support platelet adhesion/activation/aggregate formation on immobilized fibrinogen and polymerized fibrin. (Source: Journal of Thrombosis and Haemostasis)
Source: Journal of Thrombosis and Haemostasis - January 15, 2018 Category: Hematology Authors: I. Induruwa, M. Moroi, A. Bonna, J. ‐D. Malcor, J.‐M. Howes, E. A. Warburton, R. W. Farndale, S. M. Jung Tags: Original Article Source Type: research
Effect of Eptifibatide on Inflammation During Acute Pain Episodes in Sickle Cell Disease
(Source: American Journal of Hematology)
Source: American Journal of Hematology - January 11, 2018 Category: Hematology Authors: Julia E. Brittain, Ciprian Anea, Payal Desai, Jack Delaney, Adam McDonald, Stephen W. Looney, Nigel S. Key, Leslie V. Parise, Kenneth I. Ataga Tags: Correspondence Source Type: research
Effect of eptifibatide on inflammation during acute pain episodes in sickle cell disease
American Journal of Hematology,Volume 93, Issue 4, Page E99-E101, April 2018. (Source: American Journal of Hematology)
Source: American Journal of Hematology - January 11, 2018 Category: Hematology Source Type: research
